CS18: a new drug that can potentially overcome cancer drug resistance
CS18 is a candidate for further development as a drug that could become part of combination treatments to prevent or overcome cancer drug resistance.
Read More
CS18 is a candidate for further development as a drug that could become part of combination treatments to prevent or overcome cancer drug resistance.
Read MoreThe CPRIT awards will support innovative cancer research, treatments and training programs.
Read MoreDifferences in these genes help explain why Epstein-Barr Virus can have lasting health effects in some people but not others.
Read MoreThis microscopy view of the condition shows that an affected esophagus may show both normal tissue and diseased tissue with distinctive cellular characteristics.
Read MoreDuring his decades-long career, Dr. Bert O’Malley changed our understanding of endocrinology in a fundamental way.
Read MoreThis study highlights the importance of understanding the specific type of p53 mutation in each patient’s tumor, as it may influence both disease behavior and therapeutic strategies.
Read MoreDr. Mills shares his interest in stem cells and their role in cancer and gastroenterology research with students from the Stafford STEM Magnet Academy.
Read MoreWhen a surgical oncologist declines to perform surgery on a patient, there is almost always only one reason for it. The cancer has reached such
Read MoreThe new AI tool, called DeepMVP, significantly outperforms previously published models and has implications for the development of novel therapeutics.
Read MoreLearn more about a new clinical trial aimed at improving outcomes for patients with resectable mesothelioma.
Read More